Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 8/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060096 | 1.00 | PRKCA (0.35) | PRKCAATMMAPTRAB9ANPSR1 | |
| SCHEMBL6059655 | 0.96 | PRKCA (0.37) | PRKCAATMMAPTRAB9ANPSR1 | |
| SCHEMBL6059662 | 0.96 | PRKCA (0.37) | PRKCAATMMAPTRAB9ANPSR1 | |
| SCHEMBL6060891 | 0.95 | PRKCA (0.39) | PRKCAHCAR2ZDHHC20 | |
| SCHEMBL6060542 | 0.95 | PRKCA (0.39) | PRKCAHCAR2ZDHHC20 | |
| SCHEMBL6060888 | 0.95 | PRKCA (0.39) | PRKCAHCAR2ZDHHC20 | |
| SCHEMBL6060540 | 0.95 | PRKCA (0.39) | PRKCAHCAR2ZDHHC20 | |
| SCHEMBL6059915 | 0.92 | HCAR2 (0.34) | PRKCAHCAR2KEAP1NFE2L2 | |
| SCHEMBL6059913 | 0.92 | HCAR2 (0.34) | PRKCAHCAR2KEAP1NFE2L2 | |
| SCHEMBL6060257 | 0.85 | ATM (0.30) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071344-B1 | Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments | SCHERING AG (DE) | 2006-07-04 | — | — | US | disclosed |
| US-20050227951-A1 | Verification of translation | STEINMEYER ANDREAS | 2005-10-13 | — | — | US | disclosed |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | STEINMEYER ANDREAS (DE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227951-A1 | Verification of translation | CYP2R1, CYP24A1, VDR | PRKCA 3006/4885ATM 4609/4885MAPT 4572/4885 |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | CYP2R1, CYP24A1, VDR | PRKCA 801/4885ATM 4705/4885MAPT 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.